News | November 14, 2011

FDA’s Relabeling of Echo Contrast Agent Improves Patient Access

November 14, 2011 – The American Society of Echocardiography (ASE) reported that the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has recognized the value of contrast agents in echocardiography and made very positive revisions to the U.S. label for Definity, an ultrasound contrast agent produced by Lantheus Medical Imaging.

“The end of the monitoring requirements will markedly simplify the process from both the patient and laboratory perspective.  The withdrawal of monitoring and new safety data on pulmonary hypertension offers further comfort to those who were on the fence about contrast,” said Jonathan Lindner, M.D., FASE, professor of medicine and associate chief for education in the Cardiovascular Division at Oregon Health and Science University in Portland, Ore.

Contrast-enhanced ultrasound (CEUS) involves the injection of an intravenous contrast medium before performing traditional medical sonography. ASE has long supported the use of ultrasound contrast agents for cardiovascular imaging in clinical practice because they assist physicians in maximizing the accuracy of information obtained from echocardiograms, particularly in difficult-to-image patients, thus optimizing patient care. Contrast plays a role in patient safety by reducing unnecessary exposure to ionizing radiation, and is cost effective, as it reduces the need for more invasive procedures downstream and reduces the number of repeat tests. With the support of ASE representatives on their board, the Intersocietal Commission for the Accreditation of Echocardiography Laboratories (ICAEL) recognized the important role of contrast agents in improving the accuracy of echocardiograms by including it in their revised standards for the accreditation of U.S. echocardiography laboratories in December 2010. ASE and ICAEL are collaborating on a webcast educational session in February 2012 to explain these new requirements to ASE members.

At an FDA meeting about the safety of contrast agents in May 2011, Sanjiv Kaul, M.D., FASE, FACC, then-president of the ASE, was a guest speaker for the FDA and provided a presentation on the current cardiology applications of contrast echocardiography, citing multiple cases in which the administration of contrast led to diagnoses that would not otherwise have been reached. James D. Thomas, M.D., FASE, FACC, then president-elect of the Society, represented ASE and documented the clinical utility of ultrasound contrast agents for a number of indications beyond those approved by the FDA at the time, including stress echocardiography (for left ventricular opacification), vascular imaging and myocardial perfusion imaging. He noted that ASE believes that these agents have broad applications beyond those currently approved, and encourages manufacturers to perform clinical trials to seek FDA approval for additional applications.

ASE has also fought hard for appropriate reimbursement for contrast administration. In the recently published Medicare Physician Fee Schedule, the Center for Medicaid and Medicare Services rejected ASE’s request for the establishment of additional contrast-enhanced echo Ambulatory Payment Classifications (APCs), but increased the APC rate for contrast-enhanced echo by almost $60. Under the final rates, the APC rate for contrast enhanced transthoracic echo (with spectral and color Doppler) is $164 more than unenhanced procedures, but the rate for contrast-enhanced stress echo is $23.68 less than for unenhanced stress echo.

The changes to the Definity label reflect the second FDA revision of warnings about contrast agents since boxed warnings were issued in 2007. More information about the relabeling is available on the Lantheus Website.  ASE commends Lantheus for their efforts in helping to clarify the safety and value of contrast as a diagnostic tool, and supports GE Healthcare’s efforts to seek similar label modifications for Optison, a contrast agent marketed by GE Healthcare. It is ASE’s understanding that GE will be submitting a label modification request later this year.

For more information: www.asecho.org

 

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Epsilon Imaging Demonstrates Strain Imaging Integration for Echo Programs at ASE 2018
News | Cardiovascular Ultrasound | June 19, 2018
Clinical practice, along with guidelines and research, have shown that speckle tracking strain imaging can improve...
FDA Clears Bay Labs' EchoMD AutoEF Software for AI Echo Analysis
Technology | Cardiovascular Ultrasound | June 19, 2018
Cardiovascular imaging artificial intelligence (AI) company Bay Labs announced its EchoMD AutoEF software received 510(...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Olympus and Hitachi Healthcare Americas Introduce Arietta 850
News | Ultrasound Imaging | June 04, 2018
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedu
New Ultrasound Guidelines Reliably Identify Children Who Should be Biopsied for Thyroid Cancer

Image courtesy of Loyola Medicine

News | Pediatric Imaging | May 29, 2018
A Loyola Medicine study has found that new ultrasound guidelines can reliably identify pediatric patients who should be...
Samsung Receives FDA Clearance for Premium Ultrasound System RS85
Technology | Ultrasound Imaging | May 07, 2018
NeuroLogica, a subsidiary of Samsung Electronics Co. Ltd., announced the Samsung RS85 ultrasound system has received U....
3D-4D ultrasound of a fetus imaged with a GE Volusion E10 system. It shows the yoke sac. This is a baby ultrasound, also referred to as fetal ultrasound or prenatal ultrasound.

3D-4D ultrasound of a fetus imaged with a GE Volusion E10 system. It shows the yoke sac.

Feature | Ultrasound Women's Health | May 07, 2018
Below is a collection of prenatal ultrasound images from the ITN archive.
Esaote Change of Ownership Completed
News | Ultrasound Imaging | April 30, 2018
The acquisition of biomedical equipment company Esaote SpA’s share capital was completed on April 19, the company...
Overlay Init